BIT 3.33% 3.1¢ biotron limited

Ann: Appointment of a Director and Appendix 3X, page-25

  1. J8
    14,554 Posts.
    lightbulb Created with Sketch. 823
    Good appointment imho.
    This is lining up HBV preclinical I believe.


    I still think HCV is a waste of time, except for the fact that there's plenty of coinfected to deal with. BIT225 has proven almost nothing against HCV and the market is very much taken already. DYOR.

    HBV represents a bigger target than HIV imho.
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.